A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer - C21013

Millenium Pharmaceuticals0 个研究点目标入组 8 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. Male patients 18 years or older.
•2. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
•3. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.
•4. Prior surgical castration or concurrent use of an agent for medical castration (eg, GnRH analogue).
•5. PSA * 2 ng/mL at screening.
•6. Progressive disease based on PSA and/or radiographic criteria.

•1. Prior therapy with orteronel, ketoconazole, aminoglutethimide, or abiraterone.
•2. Known hypersensitivity to compounds related to orteronel, orteronel excipients, prednisone (or commercially available equivalent), or GnRH analogue.
•3. All antiandrogen therapy (including bicalutamide) is excluded within 4 weeks before the first dose of study drug. Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (eg, finasteride or dutasteride), must be discontinued 2 weeks before the first dose of study drug.
•4. Continuous daily use of oral prednisone (or commercially available equivalent), oral dexamethasone, or other systemic corticosteroids for more than 2 weeks within the 3 months before screening (inhaled, nasal, and local steroids [eg, joint injection] are allowed).
•5. Prior chemotherapy for prostate cancer, with the exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years before screening.

发起方